Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Ottawa Regional Cancer Centre
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
No trial-level evidence is linked to this axis yet.
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Pheochromocytoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tamoxifen (this asset) | Ottawa Regional Cancer Centre | P2 | B · 57 |
| Adriamycin | European Organisation for Research and Treatment of Cancer - EORTC | P3 | BB |
| Isocyclophosphamide | European Organisation for Research and Treatment of Cancer - EORTC | P3 | BB |
| Nivestim | European Organisation for Research and Treatment of Cancer - EORTC | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | Ottawa Regional Cancer Centre | P2 | B |
| Fostamatinib Disodium | National Cancer Institute (NCI) | P2 | B |
| L-Cysteinamide, D-Phenylalanyl-L-Cysteinyl-L-Phenylalanyl-D-Tryptophyl-L-Lysyl-L-Threonyl-N-(2-Hydroxy-1-(Hydroxymethyl)Propyl)-, Cyclic (2->7)-Disulfide, (R-(R*,R*))- | Vanderbilt-Ingram Cancer Center | P2 | CCC |
| Guadecitabine | National Cancer Institute (NCI) | P2 | CCC |
| Edotreotide | Excel Diagnostics and Nuclear Oncology Center | P2 | CCC |
+13 more in the Pheochromocytoma cohort
Other indications for Tamoxifen
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Carcinoma | — | P4 | BBB · 75 |
| Invasive Breast Carcinoma | — | P4 | BBB · 75 |
| Breast Fibroadenoma | — | P4 | BBB · 73 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- AdriamycinEuropean Organisation for Research and Treatment of Cancer - EORTCBB
- IsocyclophosphamideEuropean Organisation for Research and Treatment of Cancer - EORTCBB
- NivestimEuropean Organisation for Research and Treatment of Cancer - EORTCBB
- Cis-Diamminedichloroplatinum IiOttawa Regional Cancer CentreB
- Fostamatinib DisodiumNational Cancer Institute (NCI)B
Citation
Floatz Terminal. Tamoxifen in Pheochromocytoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tamoxifen-pheochromocytoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →